Annette S. Kim, MD, PhD is the Henry Clay Bryant Professor and Division Head of Molecular and Genomic Pathology at the University of Michigan. Annette S. Kim received her MD, PhD from Harvard in 1998. After a postdoc at Memorial Sloan Kettering Inst. and several years at Merck, Dr. Kim completed residency and fellowship in Hematopathology at the University of Pennsylvania in 2008.  Dr. Kim has been the Medical Director at Cooper University Hospital (2008-2009) and hematopathologist and molecular pathologist at Vanderbilt University (2009-2015) and Brigham and Women’s Hospital (2015-2023). She joined the University of Michigan in 2023. Dr. Kim’s research program has focused on the study of hematolymphoid malignancies, including miRNAs in myelodysplastic syndromes and myeloid mutational patterns, as well as on test utilization management. At the Brigham and Women’s Hospital, Dr. Kim has served as the Laboratory Director of the Heme Molecular Lab and the Translational Biomarker Core of the Center for Advanced Molecular Diagnostics. She was Co-Director of the Interpretive Genomics Program at the Dana Farber Cancer Institute, the Director of the BH3 Profiling Laboratory, and the PI of the molecular core for the Leukemia SPORE program. She has served on several national pathology committees including the College of American Pathologists Molecular Oncology and Personalized Health Care Committees, the latter as current Vice-Chair, and the Association of Molecular Pathology Board and Executive Committee as well as chairing the Hematopathology Subdivision and the Training and Education Committees. In addition, she is a member of the ASH Precision Medicine and Somatic Working Group committees and serves on a number of other national biomarker and pathology committees.